Dupilumab provides a unique therapeutic option for both patients and clinicians as the first targeted systemic drug for the treatment of moderate to severe atopic dermatitis (AD). However, a subgroup of patients taking dupilumab is either partial responders who show some improvement in the Investigator’s Global Assessment score but not enough to fulfill the primary goal or non-durable responders who achieve the therapeutic endpoint but then lose some efficacy. 

The study suggests a treatment protocol for managing dupilumab partial responders and non-durable responders that includes optimizing topical therapy, exploring alternate diagnoses, and utilizing dupilumab in combination with standard systemic immunosuppressive drugs. 

With a variety of targeted medicines for AD in the pipeline, researchers advise patients who did not respond adequately to dupilumab to stay patient and positive as the arsenal of AD therapy methods grows.